Acute Myocardial Infarction Induced by Ephedrine Alkaloids

Pharmacotherapy

Volumn 23, Issue 12 I, 2003, Pages 1645-1651

  Enders, Jason M ^a,c   Dobesh, Paul P ^a   Ellison, James N ^b  

^a ST LUKE S HOSPITAL   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c Division of Pharmacy Practice   (United States)

Author keywords

Ephedra; Ephedrine alkaloids; Myocardial infarction

Indexed keywords

ALKALOID; EPHEDRINE; METABOLIFE 356; METHYLEPHEDRINE; METHYLPSEUDOEPHEDRINE; NOREPHEDRINE; NORPSEUDOEPHEDRINE; PSEUDOEPHEDRINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOTOXICITY; CASE REPORT; CORONARY ARTERY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; EMERGENCY WARD; EPHEDRA SINICA; FEMALE; HEART CATHETERIZATION; HUMAN; INSOMNIA; SINUS RHYTHM; ST SEGMENT DEPRESSION; T WAVE; THORAX PAIN; VASOSPASM; WEIGHT REDUCTION;

ALKALOIDS; ANTI-OBESITY AGENTS; EPHEDRINE; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYTOTHERAPY;

EID: 0344011139     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.15.1645.31959     Document Type: Article

References (35)

1. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994, public law 103-417. Available from www.fda.gov/opacom/laws/dshea.html.Accessed July 18, 2003.
2. Lindsay BD. Are serious adverse cardiovascular events an unintended consequence of the Dietary Supplement Health and Education Act of 1994? [editorial]. Mayo Clin Proc 2002;77:7-9.
3. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77:12-16.
4. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
5. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink [letter]. J Clin Psychopharmacol 1997;17:437-9.
6. Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of "herbal ecstasy." J Emerg Med 1999;17:289-91.
7. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999;37:485-9.
8. Cockings JGL, Brown MA. Ephedrine abuse causing acute myocardial infarction. Med J Aust 1997;167:199-200.
9. Centers for Disease Control and Prevention. Adverse events associated with ephedrine-containing products: Texas, December 1993-September 1995. MMWR Morb Mortal Wkly Rep 1996;45:689-93.
10. Rezkalla SH, Mesa J, Sharma P, Kloner RA. Myocardial infarction temporally related to ephedra: a possible role for the coronary microcirculation. WMJ 2002;101:64-6.
11. Metabolife International, Inc. Metabolife 356. Available from www.metabolife.com/products/356_detail.htm. Accessed July 18, 2003.
12. Metabolife International, Inc. Metabolife 356 E-Z Tab. Available from www.metabolife.com/products/E-ZTab_detail.htm. Accessed July 18, 2003.
13. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet and cardiovascular diseases: a statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999;99:178-82.
14. Gurley BJ, Wang P, Gardner SF. Ephedrine-alkaloid content of nutritional supplements containing ephedra sinica (ma huang) as determined by high-performance liquid chromatography. J Pharm Sci 1998;87:1547-53.
15. Pentel P. Toxicity of over-the-counter stimulants. JAMA 1984;252:1898-903.
16. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed New York: McGraw-Hill, 2001:215-68.
17. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. JAMA 2003;289:1537-45.
18. Wiener I, Tilkian AG, Palazzolo M. Coronary artery vasospasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. Cathet Cardiovasc Diagn 1990;20:51-3.
19. To LB, Sanster JF, Rampling D, Cammens I. Ephedrine-induced cardiomyopathy. Med J Aust 1980;2;35-6.
20. Derreza H, Fine MD, Sadaniantz A. Acute myocardial infarction after use of pseudoephedrine for sinus congestion. J Am Board Fam Pract 1997;10:436-8.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
22. Jellin JM, ed. Natural Medicines Comprehensive Database. Stockton, CA: Therapeutic Research Faculty, 2003.
23. Blumethal M, Busse WR, Goldberg A, et al, eds. The complete German commission E monographs: therapeutic guide to herbal medicines, 1st ed. Austin, TX: American Botanical Council, 1998.
24. Robertson D, Frolich JC, Carr RK, et al. Effects of caffeine on plasma renin activity, catecholamines, and blood pressure. N Engl J Med 1978;298:181-6.
25. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
26. Kernan WN, Viscoli CM, Brass LM, et al. Phenyl-propanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-32.
27. Bent S, Tiedt TN, Odden MC, Shilpak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003;138:468-71.
28. Food and Drug Administration. White paper on ephedra. Evidence on the safety and effectiveness of ephedra: implications for regulation. Available from www.fda.gov/bbs/topics/NEWS/ephedra/whitepaper.html. Accessed May 2, 2003.
29. Fontanarosa PB, Rennie D, DeAngelis CD. The need for regulation of dietary supplements: lessons from ephedra [editorial]. JAMA 2003;289:1568-70.
30. Public Citizen Health Research Group. Petition to the Food and Drug Administration (FDA) requesting the ban of production and sale of dietary supplements containing ephedrine alkaloids. HRG publication #1590. Available from http://www.publiccitizen.org/publications/print_release.cfm?ID=7053. Accessed July 18, 2003.
31. National Association for Stock Car Auto Racing. Notebook: NASCAR may start testing for ephedra. Available from http://www.nascar.com/2003/news/headlines/wc/03/28/notebook_smithson/index.html. Accessed July 18, 2003.
32. State of Illinois. Blagojevich signs legislation banning sale of ephedra. Available from http://www.illinois.gov/PressReleases/PrintPressRelease.cfm?SubjectID= I&RecNum=2137. Accessed July 18, 2003.
33. American Heart Association. American Heart Association urges ban on ephedra-based supplements. Available from http://www.americanheart.org/presenter.jhtml?identifier=30106 81. Accessed July 18, 2003.
34. American Medical Association. AMA "commends" Illinois lawmakers on statewide ephedra ban. Available from http://www.ama-assn.org/ama/pub/article/2403-7705.html. Accessed July 18, 2003.
35. Sports Illustrated. Ephedra a factor, coroner finds 'significant amounts' of diet supplement. Available from http://sportsillustrated.cnn.com/baseball/news/2003/03/13/bechler_report_ap/. Accessed July 18, 2003.